Performance evaluation of the Roche Elecsys (R) CMV IgG and IgM on the modular analytics E170 : PX-5

Détails

ID Serval
serval:BIB_FC75AA53782D
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Performance evaluation of the Roche Elecsys (R) CMV IgG and IgM on the modular analytics E170 : PX-5
Titre de la conférence
12th Annnual Meeting of the European-Society-for-Clinical-Virology
Auteur(s)
Meylan P., Chappuis S., Laengin T., Bertele R.
Adresse
Istanbul, Turkey, September 27-30, 2009
ISBN
1386-6532
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
46
Série
Journal of Clinical Virology
Pages
S48
Langue
anglais
Notes
Background: Cytomegalovirus (CMV) infection of healthy individuals mostly
remains asymptomatic. However, infection during pregnancy bears the risk of
congenital infection. With this knowledge, the performances of the recently
approved Roche Elecsys® CMV IgG and IgM with two established CMV
assays, bioM´erieux Vidas® CMV-IgG and Medac® CMV-IgM-ELA, were
compared.
Methods: A total of 126 randomly-selected routine pregnancy samples and 50
pre-selected patient samples were investigated. Due to the absence of a gold
standard, discrepant results were resolved with avidity testing and/or research
neutralization assay.
Results: Comparison of routine pregnancy samples with Elecsys CMV IgG
and Vidas CMV-IgG found an agreement of 99.2%. In the same cohort,
comparison of IgM assays revealed an agreement of 97.62% between Elecsys
CMV IgM and Medac CMV-IgM-ELA with a specificity of 97.56% (93.04-
99.49%) and 99.10% (95.55-99.98%), respectively.
In pre-selected IgM-positives (according to Medac) with high-avidity IgG,
100% agreement was found between Elecsys CMV IgG and Vidas CMVIgG.
In contrast, comparison with IgM assays detected an agreement of 38%,
with Elecsys detecting only 19 positive/greyzone IgM of 50 Medac-positive
samples.
Conclusions: In pregnancy screening, this study shows a similar performance
of Elecsys CMV IgG and IgM to comparison assays. Elecsys CMV IgG is at
least as sensitive as Vidas. Elecsys CMV IgM shows a reasonable agreement
to Medac. In pre-selected IgM-positive/high-avidity IgG samples that might
reflect reactivated past infections, Elecsys CMV IgM detected less IgMpositive
samples which should reduce concern and follow-up screening in
routine pregnancy testing in cases with low risk of conceptus infection.
Web of science
Création de la notice
15/12/2009 16:11
Dernière modification de la notice
20/08/2019 17:27
Données d'usage